Targeting extracellular and juxtamembrane FGFR2 mutations in chemotherapy-refractory cholangiocarcinoma

Targeting extracellular and juxtamembrane FGFR2 mutations in chemotherapy-refractory cholangiocarcinoma

Abstract Intrahepatic cholangiocarcinoma (iCCA) has emerged as a promising candidate for precision medicine, especially in the case of activating FGFR2 gene fusions. In addition to fusions, a considerable fraction of iCCA patients reveals FGFR2 mutations, which might lead to uncontrolled activation...

Full description

Bibliographic Details
Main Authors: Michael Bitzer, Stephan Spahn, Sepideh Babaei, Marius Horger, Stephan Singer, Klaus Schulze-Osthoff, Pavlos Missios, Sergios Gatidis, Dominik Nann, Sven Mattern, Veit Scheble, Konstantin Nikolaou, Sorin Armeanu-Ebinger, Martin Schulze, Christopher Schroeder, Saskia Biskup, Janina Beha, Manfred Claassen, Kristina Ruhm, Antti Poso, Nisar P. Malek
Format: Article
Language:English
Published: Nature Portfolio 2021-09-01
Series:npj Precision Oncology
Online Access:https://doi.org/10.1038/s41698-021-00220-0

Internet

https://doi.org/10.1038/s41698-021-00220-0

Similar Items